Gsk (GLAXF) Enterprise Value (2016 - 2025)
Gsk has reported Enterprise Value over the past 11 years, most recently at -$4.7 billion for Q4 2025.
- Quarterly results put Enterprise Value at -$4.7 billion for Q4 2025, up 8.37% from a year ago — trailing twelve months through Dec 2025 was -$4.7 billion (up 8.37% YoY), and the annual figure for FY2025 was -$4.7 billion, up 8.37%.
- Enterprise Value for Q4 2025 was -$4.7 billion at Gsk, up from -$5.1 billion in the prior quarter.
- Over the last five years, Enterprise Value for GLAXF hit a ceiling of -$4.7 billion in Q4 2025 and a floor of -$9.2 billion in Q4 2022.
- Median Enterprise Value over the past 5 years was -$5.8 billion (2021), compared with a mean of -$6.2 billion.
- Biggest five-year swings in Enterprise Value: surged 32.29% in 2021 and later plummeted 59.0% in 2022.
- Gsk's Enterprise Value stood at -$5.8 billion in 2021, then crashed by 59.0% to -$9.2 billion in 2022, then skyrocketed by 30.36% to -$6.4 billion in 2023, then increased by 19.95% to -$5.1 billion in 2024, then increased by 8.37% to -$4.7 billion in 2025.
- The last three reported values for Enterprise Value were -$4.7 billion (Q4 2025), -$5.1 billion (Q4 2024), and -$6.4 billion (Q4 2023) per Business Quant data.